The mixed analyst ratings for Myriad Genetics indicate that there is no clear consensus on the stock's short-term direction. The average price target of $23.6 implies an upside, but the range of ratings suggests that the stock's performance may be influenced by other factors. The 18.0% increase in the average price target over the past month indicates that analysts have become more optimistic about the stock, but the overall mixed ratings mean that the short-term impact on the stock price is uncertain.